USPTO serial 79279617
LIGHTBIO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 8, 2021
- Examiner
- LEVINE, HOWARD B
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with LIGHTBIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,795*
Plus Government fees of $1,625
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Hampton TW12 2ER, GB
Hampton TW12 2ER, GB
Hampton TW12 2ER, GB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rebecca Liebowitz
Rebecca Liebowitz Venable LLPP.O. Box 34385Washington, DC 20043-9998UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical preparations, enzymes and DNA for the preparation of nucleic acid for scientific research; chemicals for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; enzymes for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; DNA extracts and cassettes for scientific and research use; DNA extracts for use in scientific research in the field of agri-biotechnology and nanotechnology; nucleic acids comprising natural and unnatural nucleotides for use in laboratory nanotechnology applications, namely, data storage, data retrieval and computing; nucleic acid analogues comprising synthetic backbones or a mixture of natural and synthetic backbones for use in laboratory nanotechnology applications, namely, data storage, data retrieval and computing; composites of nucleic acids or nucleic acid analogues with organic and inorganic chemicals for use in laboratory nanotechnology applications, namely, data storage, data retrieval and computing; nucleic acid analogues with organic and inorganic chemicals for laboratory use in labelling, imaging and sensing applications; nucleic acid analogues with organic and inorganic chemicals for laboratory use in smart materials; two-dimensional and three-dimensional nucleic acid analogues with organic and inorganic chemicals for laboratory use in creating nanostructures and scaffolds; Nucleic acids comprising natural and unnatural nucleotides for laboratory use; nucleic acid analogues comprising synthetic backbones or a mixture of natural and synthetic backbones for laboratory use; composites of nucleic acids or nucleic acid analogues with organic and NAC inorganic chemicals for laboratory use; all the aforesaid goods for use in laboratory nanotechnology applications, namely, data storage, data retrieval and computing | ACTIVE | — |
| 005 | Vaccines; DNA based vaccines; DNA extracts, namely, nucleic acid sequences and chemical reagents for medical use; therapeutic DNA, namely, nucleic acid sequences and chemical reagents for medical and veterinary purposes; nucleic acids comprising natural and unnatural nucleotides for medical and veterinary purposes; nucleic acid analogues comprising synthetic backbones or a mixture of natural and synthetic backbones for medical and veterinary purposes; composites of nucleic acids or nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes; nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in labeling, imaging and sensing applications; nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in smart materials; two-dimensional and three-dimensional nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in creating nanostructures and scaffolds | ACTIVE | — |
| 009 | Scientific apparatus and instruments, namely, apparatus for amplifying DNA, namely, reactors and bioreactors; apparatus for manufacturing DNA, namely, reactors and bioreactors; apparatus for processing DNA, namely, reactors and bioreactors; electronic components, namely, nucleic acid analogues in the nature of electric and power wires, semi-conductors, transistors, rectifiers, diodes, light emitting diodes and energy storage systems in the nature of devices for energy storage, namely, batteries, fuel cells configured for energy storage, and electrochemical devices configured for energy storage, namely, electrolysers; electric and power wires comprised of nucleic acid composites (NACs) semi-conductors, transistors, rectifiers, diodes, light emitting diodes and energy storage systems in the nature of devices for energy storage, namely, batteries, fuel cells configured for energy storage, and electrochemical devices configured for energy storage, namely, electrolysers, each comprised of nucleic acid composites (NACs); labeling, imaging and sensing apparatus comprising of nucleic acid composites (NACs) for laboratory and research use; smart materials in the nature of DNA chips, DNA microarrays, comprised of nucleic acid composites; two-dimensional and three-dimensional nucleic acid composites (NACs) in the nature of DNA chips, DNA microarrays for creating nanostructures and scaffolds for use in electronic components and materials, namely, electrical conductors; parts and fittings for all the aforesaid technology and parts and fittings for all the aforesaid goods, namely, electrical cables, display screens, transmitters | ACTIVE | — |
| 040 | Chemical treatment of DNA to form DNA extracts; custom manufacture of therapeutic DNA by the manipulation of DNA into DNA extracts or cassettes | ACTIVE | — |
| 042 | Scientific and technological services and research and design relating thereto, namely, chemical and biological analysis and research services; DNA analysis services for scientific research purposes; scientific research and development into the creation of DNA extracts; scientific research, analysis, design and development relating to DNA based drugs and therapies; scientific research and development in the fields of gene therapy, genetic diagnostics, agri-biotechnology and nanotechnology, all in the field of gene therapy; consultancy relating to the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by LightBio Limited
- Other trademarks owned by LightBio Limited
- Other trademarks owned by LightBio Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named LIGHTBIO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 8, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Oct 24, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 28, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 28, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 8, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 8, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 23, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 23, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 21, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Mar 3, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 3, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 3, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 16, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 16, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 16, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 16, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 16, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 11, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 11, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 11, 2021 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jan 7, 2021 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jan 7, 2021 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 7, 2021 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 17, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 17, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 15, 2020 | ALIE | ASSIGNED TO LIE | — |
| Sep 21, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 10, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 25, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 25, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 6, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 4, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 3, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 2, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 2, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 27, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |